Lupin launches Levothyroxine Sodium Tablets USP

Lupin announced the launch of Levothyroxine Sodium Tablets USP, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc's Synthroid Tablets. It is indicated for:

Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism

Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer

Levothyroxine Sodium Tablets, 25 meg, SO meg, 75 meg, 88 meg, 100 meg, 112 meg, 125 meg, 137 meg, 150 meg, 175 meg, 200 meg, and 300 meg had an annual sales of approximately USD 2.5 billions in the U.S (IQVIA MAT January 2019).

Powered by Capital Market - Live News